Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
This article has been co-published with permission in the European Heart Journal and EuroIntervention. All rights reserved. © the European Society of Cardiology and the Authors 2023. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article..
Since the publication of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) Guidelines for the Management of Arterial Hypertension, several high-quality studies, including randomised, sham-controlled trials on catheter-based renal denervation (RDN) were published, confirming both the blood pressure (BP)-lowering efficacy and safety of radiofrequency and ultrasound RDN in a broad range of patients with hypertension, including resistant hypertension. A clinical consensus document by the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) on RDN in the management of hypertension was considered necessary to inform clinical practice. This expert group proposes that RDN is an adjunct treatment option in uncontrolled resistant hypertension, confirmed by ambulatory BP measurements, despite best efforts at lifestyle and pharmacological interventions. RDN may also be used in patients who are unable to tolerate antihypertensive medications in the long term. A shared decision-making process is a key feature and preferably includes a patient who is well informed on the benefits and limitations of the procedure. The decision-making process should take (i) the patient's global cardiovascular (CV) risk and/or (ii) the presence of hypertension-mediated organ damage or CV complications into account. Multidisciplinary hypertension teams involving hypertension experts and interventionalists evaluate the indication and facilitate the RDN procedure. Interventionalists require expertise in renal interventions and specific training in RDN procedures. Centres performing these procedures require the skills and resources to deal with potential complications. Future research is needed to address open questions and investigate the impact of BP-lowering with RDN on clinical outcomes and potential clinical indications beyond hypertension.
| Errataetall: |
ErratumIn: Eur Heart J. 2023 Jul 14;44(27):2439. - PMID 37285272 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
European heart journal - 44(2023), 15 vom: 17. Apr., Seite 1313-1330 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barbato, Emanuele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antihypertensive Agents |
|---|
| Anmerkungen: |
Date Completed 18.04.2023 Date Revised 07.06.2023 published: Print ErratumIn: Eur Heart J. 2023 Jul 14;44(27):2439. - PMID 37285272 Citation Status MEDLINE |
|---|
| doi: |
10.1093/eurheartj/ehad054 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352966718 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352966718 | ||
| 003 | DE-627 | ||
| 005 | 20231226054923.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/ehad054 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352966718 | ||
| 035 | |a (NLM)36790101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barbato, Emanuele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2023 | ||
| 500 | |a Date Revised 07.06.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Eur Heart J. 2023 Jul 14;44(27):2439. - PMID 37285272 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This article has been co-published with permission in the European Heart Journal and EuroIntervention. All rights reserved. © the European Society of Cardiology and the Authors 2023. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article. | ||
| 520 | |a Since the publication of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) Guidelines for the Management of Arterial Hypertension, several high-quality studies, including randomised, sham-controlled trials on catheter-based renal denervation (RDN) were published, confirming both the blood pressure (BP)-lowering efficacy and safety of radiofrequency and ultrasound RDN in a broad range of patients with hypertension, including resistant hypertension. A clinical consensus document by the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) on RDN in the management of hypertension was considered necessary to inform clinical practice. This expert group proposes that RDN is an adjunct treatment option in uncontrolled resistant hypertension, confirmed by ambulatory BP measurements, despite best efforts at lifestyle and pharmacological interventions. RDN may also be used in patients who are unable to tolerate antihypertensive medications in the long term. A shared decision-making process is a key feature and preferably includes a patient who is well informed on the benefits and limitations of the procedure. The decision-making process should take (i) the patient's global cardiovascular (CV) risk and/or (ii) the presence of hypertension-mediated organ damage or CV complications into account. Multidisciplinary hypertension teams involving hypertension experts and interventionalists evaluate the indication and facilitate the RDN procedure. Interventionalists require expertise in renal interventions and specific training in RDN procedures. Centres performing these procedures require the skills and resources to deal with potential complications. Future research is needed to address open questions and investigate the impact of BP-lowering with RDN on clinical outcomes and potential clinical indications beyond hypertension | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a renal sympathetic denervation | |
| 650 | 4 | |a resistant hypertension | |
| 650 | 4 | |a uncontrolled hypertension | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 700 | 1 | |a Azizi, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Schmieder, Roland E |e verfasserin |4 aut | |
| 700 | 1 | |a Lauder, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Böhm, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Brouwers, Sofie |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Rosa Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Dudek, Dariusz |e verfasserin |4 aut | |
| 700 | 1 | |a Kahan, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Kandzari, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Lüscher, Thomas F |e verfasserin |4 aut | |
| 700 | 1 | |a Parati, Gianfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Pathak, Atul |e verfasserin |4 aut | |
| 700 | 1 | |a Ribichini, Flavio L |e verfasserin |4 aut | |
| 700 | 1 | |a Schlaich, Markus P |e verfasserin |4 aut | |
| 700 | 1 | |a Sharp, Andrew S P |e verfasserin |4 aut | |
| 700 | 1 | |a Sudano, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Volpe, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Tsioufis, Costas |e verfasserin |4 aut | |
| 700 | 1 | |a Wijns, William |e verfasserin |4 aut | |
| 700 | 1 | |a Mahfoud, Felix |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal |d 1983 |g 44(2023), 15 vom: 17. Apr., Seite 1313-1330 |w (DE-627)NLM012617253 |x 1522-9645 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:15 |g day:17 |g month:04 |g pages:1313-1330 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurheartj/ehad054 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 15 |b 17 |c 04 |h 1313-1330 | ||